In ovarian cancer and pancreatic cancer26, 27, miR-214 has been found to act as an oncogene to promote cell proliferation and cisplatin resistance via the downregulation of PTEN and activation of the PI3K/AKT signalling pathway. This evidence concerns the gene PTEN and ovarian carcinoma.